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The therapy of atopic dermatitis has always been so difficult and unsatisfactory that
any method of treatment which appears to be promising should be recorded. In view of this,
I wish to report some recent experiences with the administration of sodium para-amino-
beuzoate in patients with atopic dermatitis.' There is as yet no rationale for this therapy.
The impetus for this investigation was the observation of the marked reduction of the
inflammatory infiltrate in the lesions of lupus erythematosus in patients treated with
sodium para-aminobenzoate as reported by Zarafonetis, Grekin and Curtis (1) and some
personal observations of the decrease in the amount of infiltration in the lesions of patients
with this disease so treated. Recently the above investigators have extended their observa-
tions with para-aminobeuzoate therapy of seleroderma, dermatomyositis, granuloma
fungoides and dermatitis herpetiformis (2).
Sodium para-aminobenzoate has been administered orally in doses of 2 grams every two
hours during waking hours to sixteen patients with atopic dermatitis, during the past ten
months. These cases were of varying severity and duration and were approximately equally
distributed with reference to sex. The age range of the patients was from 8 years to 56.
No roentgen therapy was administered and topical treatment was limited to the employ-
ment of colloid baths, simple non-medicated shake lotions, mild diluted Burow's solution
compresses and bland emollients. A few of the patients received ultraviolet irradiation at
weekly intervals. No dietary changes were imposed, and only two of the patients were
hospitalized, each for a period of less than two weeks. Eight of the patients presented severe
generalized eruptions and of these, five improved remarkably, with lessening or disappear-
ance of the infiltration in the involved areas and diminution or cessation of the pruritus.
One of the patients in this group improved initially, but after several weeks, clinical re-
lapse occurred while the patient was taking the medication. This failed to yield to con-
tinued administration of sodium para-aminobenzoate. In another instance among the sev-
ere cases, there was no demonstrable response to the therapy after two months, and it was
abandoned. In another, the patient developed redness and burning in the involved areas
during the first 24 hours of treatment (Herxheimer type reaction?), discontinued the
treatment after two days and has failed to return for further observation.
In eight of the patients, the eruption was classified as mild to moderately severe with
the lesions limited to localized symmetrical involvement of the fiexural areas or patchy
involvement of the wrists. In four of these patients, the eruption improved or disappeared
entirely and there have thus far been no recurrences. In two, there was initial improvement
but subsequent relapse, which was not controlled with further therapy, and in two, there
was no apparent effect from the treatment.
Where effective response to treatment with sodium para-aminobenzoate occurred, three
to four weeks of therapy were necessary before any appreciable subjective or objective
improvement was observed. One patient with severe generalized atopic dermatitis has
remained free of his eruption for ten months but has had two relapses. One of these occurred
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when the medication was deliberately discontinued for two weeks, and the other when
placebo tablets were substituted. With both episodes, the eruption promptly subsided
within three weeks following the resuming of sodium para-aminobenzoate therapy.
There were no severe untoward reactions. A few of the patients complained of some
nausea and anorexia and one experienced some vomiting which subsided on reducing the
dose of the drug. Complete blood counts and urine analyses were performed at irregular
intervals. There have been no changes in the hemograms. Reducing substance was found
in the urine of some of these patients, but this was not a constant reaction since the total
average amount of sodium para-aminobenzoate administered daily was only about 10 to
14 grams (3). Among a separate group of patients who were given sodium para-aminoben-
zoate for dermatological diseases other than atopic dermatitis, a fine vesicular dermatitis
of the face and trunk has been observed in two instances. The eruption subsided with dis-
continuation of the treatment within one week in both cases.
Follow-up observation has ranged from only a few weeks in some cases up to ten months
in one patient and seven months in a second, and several have been observed for three or
more months. The patient who has been followed for ten months has remained completely
clear at this writing. A few patients with lichen simplex chronicus have also been treated
with sodium para-aminobenzoate, but the results thus far have not been impressive.
Summary and Conclusion: Sixteen patients with chronic atopic dermatitis have been
treated with sodium para-aminobenzoate, 2 grams every two hours administered orally.
For the most part, only simple topical remedies have been used concomitantly. The re.
sponse thus far in approximately one-half of these patients has been excellent with diminu-
tion or disappearance of the infiltration in the involved areas and reduction or cessation
of the pruritus a rather constant effect. In about one-fourth of the patients, there has been
initial improvement but subsequent relapse which did not respond to continued treatment.
In about 25% of the cases, the effects of this therapy were unsatisfactory or equivocal.
Where the therapy is effective, it apparently must be continued indefinitely, or at least
over long periods of time, although this point needs further evaluation. Form these pre-
liminary observations with this small series of patients, sodium para-aminobensoate ther-
apy appears to be of value in the management of patients with atopic dermatitis.2
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These studies are being extended in the Dermatological Clinics of the University of
Cincinnati, and subsequent detailed reports will include histologic studies, photographs,
case histories and other pertinent data.
